SCHEMBL5115722

SCHEMBL5115722

CCOC(=O)C1(C(=O)OCC)CC1(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
ALDH1A1 P00352 3/20 0.42
OPRM1 P35372 7/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALOX15 P16050 2/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
SOAT1 P35610 1/20 0.39
ATM Q13315 1/20 0.38
OPRD1 P41143 2/20 0.38
OPRK1 P41145 2/20 0.38
SLC22A1 O15245 1/20 0.38
SLC6A4 P31645 1/20 0.38
ADRA1A P35348 1/20 0.38
KCNH2 Q12809 1/20 0.38
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5107238 0.89 OPRM1 (0.41) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL12764947 0.87 POLB (0.40) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL11581057 0.85 ALOX15 (0.48) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL4671349 0.84 POLB (0.43) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL10950638 0.81 POLB (0.44) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL1751418 0.79 POLB (0.43) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL6736700 0.78 POLB (0.46) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL30706658 0.77 POLB (0.42) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL11218074 0.77 POLB (0.42) POLBALDH1A1OPRM1LMNAHSD17B10
SCHEMBL27692286 0.77 POLB (0.42) POLBALDH1A1OPRM1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 US disclosed
CN-119677749-A Azaquinazoline pan KRAS inhibitors 米拉蒂治疗股份有限公司 2025-03-21 CN disclosed
US-20190248746-A1 CYCLOPROPYL UNSATURATED QUINOLINE COMPOUND USED AS LEUKOTRIENE RECEPTOR ANTAGONIST AND APPLICATIONS THEREOF GUANGDONG MOLTECH PHARMA CO LTD (CN) 2019-08-15 US disclosed
US-10315997-B2 Cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof GUANGDONG MOLTECH PHARMA CO., LTD. (CN) 2019-06-11 US disclosed
US-20180118687-A1 CYCLOPROPYL UNSATURATED QUINOLINE COMPOUND USED AS LEUKOTRIENE RECEPTOR ANTAGONIST AND APPLICATIONS THEREOF GUANGDONG MOLTECH PHARMA CO., LTD. (CN) 2018-05-03 US disclosed
US-7348344-B2 Polysubstituted 1,1-pyridyloxycyclopropanamine compounds LES LABORATOIRES SERVIER (FR) 2008-03-25 US disclosed
US-20070027191-A1 Polysubstituted 1,1-pyridyloxycyclopropanamine compounds LES LABORATOIRES SERVIER (FR) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248746-A1 CYCLOPROPYL UNSATURATED QUINOLINE COMPOUND USED AS LEUKOTRIENE RECEPTOR ANTAGONIST AND APPLICATIONS THEREOF LTC4S, LTB4R, CYSLTR1 POLB 3501/4885ALDH1A1 1624/4885OPRM1 972/4885
US-20180118687-A1 CYCLOPROPYL UNSATURATED QUINOLINE COMPOUND USED AS LEUKOTRIENE RECEPTOR ANTAGONIST AND APPLICATIONS THEREOF LTC4S, LTB4R, CYSLTR1 POLB 3551/4885ALDH1A1 1566/4885OPRM1 927/4885
US-20070027191-A1 Polysubstituted 1,1-pyridyloxycyclopropanamine compounds CHRM1, CHRNA1, CHRNA9 POLB 2363/4885ALDH1A1 680/4885OPRM1 39/4885
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS POLB 1520/4885ALDH1A1 3667/4885OPRM1 2625/4885
US-10315997-B2 Cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof LTC4S, LTB4R, CYSLTR1 POLB 3551/4885ALDH1A1 1566/4885OPRM1 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.